Business
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n  Company sees a significant market opportunity for cPass as a potential immunity monitoring tool for schools, businesses and healthcare providers to determine the future need for booster shots or other measures to prevent virus spread CEO to discuss cPass on Fox Business Network ‘Varney & Company’ at 11:40 am on August 23, 2021 Validation paves the way for launch of cPass testing at Provista in September 2021 New York, NY, and Tel Aviv, ISRAEL, Aug. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the cPass Neutralizing Antibody Blood Test into production and expects to launch cPass in September 2021. The cPass ELISA blood test has received Emergency Use Authorization from the FDA for the detection of neutralizing antibodies (NAbs) that will allow healthcare professionals and patients to monitor key biomarkers of COVID-19 immunity. Todos Medical CEO Gerald Commissiong has been scheduled to appear on Fox Business Network show Varney & Company at 11:40 am ET on Monday, August 23, 2021 to discuss cPass and how it is expected to empower healthcare professionals and patients with a new tool to monitor their immunity to COVID-19 as booster shots are being rolled out in the United States.  There are a rising number of breakthrough infections and the cPass may represent a way to identify those at greatest risk. “As we begin to see the impact of breakthrough infections with the Delta variant throughout the United States, we expect the FDA to authorize widespread access to booster shots in the weeks ahead,” said Gerald Commissiong, President & CEO of Todos Medical. “Vaccinated and unvaccinated patients are certainly looking for solutions to understand their level of risk to the Delta variant.  Likewise, many physicians are looking for objective data to help them manage their patients. cPass will help provide this key information on neutralizing antibody levels in vaccinated patients and patients that acquired their immunity through natural infection.  The test allows both the patient and the physician to be more informed ...